Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Torsemide

Drug and asset intelligence for Torsemide with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Micro Labs →

Recent signals(2)

RegulatoryAugust 3, 2026

FDA Approves Torsemide Application ANDA217239 from Micro Labs

The FDA has approved the ANDA217239 application for Torsemide submitted by Micro Labs.

RegulatoryJuly 12, 2026

FDA Grants Approval for Torsemide ANDA217239 by Micro Labs

The FDA has granted approval for the ANDA217239 application for Torsemide submitted by Micro Labs.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Micro Labs — Torsemide

July 12, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiovascular →
Cardiovascular · Diuretic →
Diuretic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.